Skip to main content
Premium Trial:

Request an Annual Quote

Dicerna Earns $5M Milestone as Partner Kyowa Picks up Cancer Drug


Dicerna Pharmaceuticals announced this week that it has earned a $5 million milestone payment after partner Kyowa Hakko Kirin decided to further develop an oncology drug candidate covered by the companies' drug-development alliance.

Kyowa's move comes after the Dicer-substrate drug, which is formulated using Kyowa's proprietary antibody-based delivery technology, demonstrated the ability to trigger complete tumor regression in an animal model of an undisclosed human cancer, Dicerna said.

In comparison, “the current chemical standard of care achieved only a slowing of the tumor growth rate, as was expected,” the company added.

Kyowa will now assume all responsibility for continuing the candidate's development, while Dicerna maintains the right to co-promote the drug in the US and share the profits on a 50/50 basis.

In light of the positive results, Dicerna said that Kyowa has also elected to add a second oncology target to the companies' partnership.

Dicerna and Kyowa first began working together nearly two years ago (GSN 1/7/2010). Under the deal, Dicerna received $4 million upfront and stands to receive up to $120 million in research funding and milestones in exchange for the rights to use the Dicer-substrate technology against the unnamed cancer target.

About a year later, the companies expanded their arrangement to include immunologic and inflammatory diseases. Specific terms of the expanded deal were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.